Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiro Tadokoro

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 10, 2019
[Acquired hemophilia A requiring plasma exchange and mechanical ventilation]Wataru Takahashi, Motoshi Ichikawa, Shiho Furuichi, et al.
International Journal of Hematology|April 4, 2022
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemiaAtsushi Marumo, Satoshi Wakita, Kaoru Morita, et al.
Cancer Science|January 7, 2023
Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemiaSatoshi Wakita, Atsushi Marumo, Kaoru Morita, et al.
Blood Advances|August 27, 2021
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemiaSatoshi Wakita, Masahiro Sakaguchi, Iekuni Oh, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 10, 2019
[Acquired hemophilia A requiring plasma exchange and mechanical ventilation]Wataru Takahashi, Motoshi Ichikawa, Shiho Furuichi, et al.
International Journal of Hematology|April 4, 2022
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemiaAtsushi Marumo, Satoshi Wakita, Kaoru Morita, et al.
Cancer Science|January 7, 2023
Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemiaSatoshi Wakita, Atsushi Marumo, Kaoru Morita, et al.
Blood Advances|August 27, 2021
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemiaSatoshi Wakita, Masahiro Sakaguchi, Iekuni Oh, et al.
Pageof 2